• Nicolas Verheyen, Johannes Auer, Nikolaos Bonaros, Tamara Buchacher, Daniel Dalos, Michael Grimm, Agnes Mayr, Anna Rab, Sebastian Reinstadler, Daniel Scherr, Gabor G Toth, Thomas Weber, David K Zach, Marc-Michael Zaruba, Daniel Zimpfer, Peter P Rainer, and Gerhard Pölzl.
• Division of Cardiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036, Graz, Austria. nicolas.verheyen@medunigraz.at.
• Wien. Klin. Wochenschr. 2024 Oct 1; 136 (Suppl 15): 571597571-597.

AbstractHypertrophic cardiomyopathy (HCM) is the most common inherited heart disease that is characterized by left ventricular hypertrophy unexplained by secondary causes. Based on international epidemiological data, around 20,000-40,000 patients are expected to be affected in Austria. Due to the wide variety of clinical and morphological manifestations the diagnosis can be difficult and the disease therefore often goes unrecognized. HCM is associated with a substantial reduction in quality of life and can lead to sudden cardiac death, especially in younger patients. Early and correct diagnosis, including genetic testing, is essential for comprehensive counselling of patients and their families and for effective treatment. The latter is especially true as an effective treatment of outflow tract obstruction has recently become available in the form of a first in class cardiac myosin ATPase inhibitor, as a noninvasive alternative to established septal reduction therapies. The aim of this Austrian consensus statement is to summarize the recommendations of international guidelines with respect to the genetic background, pathophysiology, diagnostics and management in the context of the Austrian healthcare system and resources, and to present them in easy to understand algorithms.© 2024. The Author(s).

15 keywords...

hide…